Pharmaceutical

Rystiggo receives FDA approval, strengthening UCB’s myasthenia gravis portfolio

UCB's Rystiggo has been granted FDA approval to treat myasthenia gravis in anti-AchR or anti-MuSK antibody-positive adults.

Jun 27, 2023 - 20:00
Rystiggo receives FDA approval, strengthening UCB’s myasthenia gravis portfolio
UCB's Rystiggo has been granted FDA approval to treat myasthenia gravis in anti-AchR or anti-MuSK antibody-positive adults.
Read the original article

Tags:

Previous Article

Pfizer takes on haemophilia B gene therapy market with new FDA application

Next Article

Wane in Covid demand hurts Walgreens as profits drop to $118m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine 

FDA clears Novavax to resume trials of Covid-19 and flu...

Nov 13, 2024

How abortion access changed in the first year after Roe v. Wade, in 8 charts

How abortion access changed in the first year after Roe...

Jun 24, 2023

STAT+: Humana CEO Bruce Broussard to step down next year

STAT+: Humana CEO Bruce Broussard to step down next year

Oct 12, 2023